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Abstract
We herein report two cases showing long-term complete remission (CR) in response to S-1
monotherapy. Case 1 was a 65-year-old male diagnosed with an advanced poorly differentiated
adenocarcinoma of the stomach with paraaortic lymph node metastases, which disappeared after
S-1 monotherapy. Subsequently a total gastrectomy was performed, and histological CR was
evident. His progress is presently uneventful without recurrence 50 months after surgery. Case 2
was a 59-year-old female who underwent a total gastrectomy with a jejunal pouch. The resected
tumor was a medullary type poorly differentiated adenocarcinoma infiltrating the serosa and
involving the regional lymph nodes. One year after surgery, endoscopy revealed a recurrent tumor
in the jejunal pouch. After the administration of S-1, this recurrent tumor completely disappeared,
and she has since maintained CR for 39 months. These cases suggest that a subgroup of patients
with advanced gastric cancer may attain CR with S-1 monotherapy.
Introduction
S-1 is an oral antitumor agent that exploits the biochemi-
cal modulation of 5-fluorouracil (FU) pharmacokinetics.
S-1 contains tegafur, gemistat and otastat potassium.
Gemistat inhibits 5-FU degradation and maintains pro-
longed 5-FU concentrations. Otastat potassium alleviates
the gastrointestinal toxicity induced in the host by 5-
FU.[1] In phase II studies, S-1 has demonstrated high
response rate for advanced gastric cancers without serious
adverse reactions.[2,3] However, complete responses
(CRs) with long-term survival are rare.[2,4,5] We report
herein two cases of advanced gastric cancer showing long-
term CR after S-1 monotherapy.
Case presentation
Case 1
A 65-year-old man complained of epigastric discomfort,
dysphagia and vomiting. Endoscopic examination
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showed a giant irregular tumor in the cardia of the stom-
ach (Fig. 1), and a biopsy revealed a poorly differentiated
adenocarcinoma with a medullary growth pattern (Fig. 2).
Abdominal computed tomography (CT) demonstrated
metastases to the paraaortic lymph nodes. There was no
metastasis to liver, peritoneum or other distant organs.
The tumor was clinically diagnosed as stage IV (cT3, cN3,
cH0, cP0, cM0) according to the general rules of the Japa-
nese Classification of Gastric Carcinomas.[6] S-1 (TS-1®,
Taiho Pharmaceutical Co., Ltd.) at a dose of 120 mg/day
was administrated orally for four weeks, followed by a
two-week period of no treatment (4-week regimen). This
therapeutic schedule was thereafter repeated four times.
No adverse events were observed during the S-1 therapy.
With the regimen, the gastric cancer remarkably decreased
in size and the paraaortic lymph node metastases disap-
peared. A total gastrectomy with regional lymph node dis-
section was performed, and the removed specimen
showed a scar in the cardia (Fig. 3). Microscopically, the
scar consisted of regenerative mucosa and fibrosis with
aggregations of histiocytes in the submucosa, partially dis-
rupted muscularis propria and subserosa (Fig. 4). No
lymph node metastases were found and some of the dis-
sected lymph nodes (paracardial nodes and nodes along
the gastroepiploic, left gastric and common hepatic arter-
ies) showed fibrosis, indicating histological assessment to
be a CR to S-1 therapy. The patient continued to be
administered S-1 at a dose of 100 mg/day for two weeks,
followed by two weeks' rest (2-week regimen) with 12
cycles for one year after surgery in our outpatient clinic,
and his progress was uneventful with neither recurrence
nor metastasis 50 months after surgery.
Case 2
A 59-year-old female underwent a total gastrectomy with
regional lymph node dissection and a jejunal pouch with
Roux-en-Y reconstruction for a tumor (6.1 × 5.1 cm in
size) in the upper corpus. Exfoliative cytology of the peri-
toneal lavage fluid during the operation was positive for
adenocarcinoma (CY1). There was no metastasis to the
liver. Microscopically, the tumor was a medullary type
poorly differentiated adenocarcinoma with lymphoid
stroma, infiltrating through the serosa (pT3) and involv-
ing regional lymph nodes (pN3; number of metastasis-
positive per dissected lymph nodes, 9/23). Based on the
surgical findings, the tumor was diagnosed as stage IV
(pT3, pN3, sH0, sP0, sM0, CY1), [6] and adjuvant chem-
otherapy combining 5-FU (total 150 mg), methotrexate
(900 mg) and leukovorin (45 mg) was subsequently per-
formed. One year after the operation, endoscopy showed
Gastroscopy reveals a giant tumor with ulceration in the car- dia Figure 1
Gastroscopy reveals a giant tumor with ulceration in the car-
dia.
A biopsy specimen showing medullary growth of a poorly dif- ferentiated adenocarcinoma (hematoxylin and eosion stain,  ×88) Figure 2
A biopsy specimen showing medullary growth of a poorly dif-
ferentiated adenocarcinoma (hematoxylin and eosion stain, 
×88).Cases Journal 2008, 1:405 http://www.casesjournal.com/content/1/1/405
Page 3 of 5
(page number not for citation purposes)
a tumor in the jejunal pouch along the suture line (Fig.
5A), and examination of a biopsy specimen revealed a
poorly differentiated adenocarcinoma. CT demonstrated
an intraluminal tumor in the jejunal pouch without any
other recurrence. A course of chemotherapy consisting S-
1 (2-week regimen) was feasible and repeated 10 times in
an outpatient clinic. During the therapy, the recurrent
tumor in jejunal pouch completely disappeared (Fig. 5B),
and a biopsy revealed no remnant tumor tissue. The
patient has now been well without any evidence of recur-
rence for 39 months.
Discussion
This report documents two cases of advanced (stage IV)
gastric cancer showing long-term CR to S-1 monotherapy;
In case 1, CR was histologically verified in the surgically
resected stomach, and in case 2 this was presented for a
suture line recurrence in the jejunal pouch.
In phase II studies of S-1 in patients with advanced gastric
cancer, the overall response rate has been approximately
40–50%.[2,3] A retrospective analysis of single-agent
chemotherapy of S-1 for patients with advanced gastric
cancer revealed it to be modestly effective with a 26–38%
in response rate.[4,5] However, CR was rare with an inci-
dence of only 2–4%[2,4,5] and histological verification in
surgically resected stomachs was extremely rare. Mori et
al. reported a patient with histological CR after a 2-week
regimen of S-1 as single-agent chemotherapy for an
advanced cancer.[7] In that case; the biopsy specimen fea-
tured a signet-ring cell type of poorly differentiated aden-
ocarcinoma. The response rate for poorly differentiated
(diffuse type) adenocarcinomas is reported to be higher
than for well differentiated (intestinal type) lesions.[3] S-
1 is also effective against the two present cases diagnosed
as medullary subtype of poorly differentiated histology.
Few reports have documented advanced gastric cancer
with long-term remission after neoadjuvant chemother-
apy with S-1 alone; two patients with advanced or meta-
static gastric cancer, who responded to S-1 monotherapy
and demonstrated clinical CR for about 4 years.[8,9] In
another report, a very short course of S-1 alone achieved
long-term CR of metastatic gastric cancer.[10] Curative
surgery following downstaging with S-1 monotherapy has
The scar found in the cardia of the resected stomach  (arrows) Figure 3
The scar found in the cardia of the resected stomach 
(arrows).
Histologically, regenerative mucosa and fibrosis with aggrega- tion of histiocytes are evident in the scar without any cancer  tissue (hematoxylin and eosion stain, ×5) Figure 4
Histologically, regenerative mucosa and fibrosis with aggrega-
tion of histiocytes are evident in the scar without any cancer 
tissue (hematoxylin and eosion stain, ×5).
Endoscopic picture of the broad-based tumor in the jejunal  pouch Figure 5
Endoscopic picture of the broad-based tumor in the jejunal 
pouch. B After S-1 chemotherapy, the recurrent tumor has 
disappeared and a scar is apparent in the jejunal pouch 
(arrows).Cases Journal 2008, 1:405 http://www.casesjournal.com/content/1/1/405
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also been successfully performed for metastatic disease
patients with long-term CR after surgery.[11]
Kimura et al. devised an alternative dosing regimen for S-
1, i.e. 2-week regimen, and conducted a retrospective
study to evaluate the efficacy and feasibility of this sched-
ule in comparison with the 4-week regimen.[12] In their
study, the incidence of adverse reactions tend to be lower
in the 2-week regimen group (77%) than in the 4-week
group (93%), with response rates of 23% and 21%,
respectively. In the present case 1, the standard 4-week
regimen was well tolerated, and in case 2, the 2-week reg-
imen was more feasible because of toxicity at the standard
dose; both cases fortunately showed long-term CR.
Jejunal pouch recurrence after gastrectomy for gastric can-
cer has rarely been described.[13,14] Interestingly, the ear-
lier tumors, like the current case, were medullary type
poorly differentiated adenocarcinomas characterized by a
location in the upper part of the stomach, grossly expan-
sive growth, frequently vascular permeation, and simulta-
neous liver metastasis, but not jejunal pouch
recurrence.[15] The cause of pouch recurrence is specu-
lated that exfoliated cancer cells were intraluminally
implanted at the jejunal mucosa, or extraluminally trans-
planted by the stapling device.[13] Alternatively, our spec-
ulation of the cause is lymphatic theory because of the fact
that the tumor of the present case 2 had extensive lymph
node metastasis.
In conclusion, the two documented cases of advanced gas-
tric cancer showed long-term CR in response to S-1 mon-
otherapy. At present, a standard neoadjuvant strategy for
advanced gastric cancer has not been established, but oral
intake S-1, which is desirable in the outpatient setting
because of its feasibility and mild toxicity, might prove to
be considered as a possible alternative chemotherapeutic
regimen for such patients, but we definitely need large
randomized controlled trial.
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